Skip to main content

Table 1 Clinical features of PDAC patients analyzed by ELISA

From: Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

Characteristics

  

N

%a

Gender

    
 

Male

 

39

57

 

Female

 

30

43

Age (y)

    
 

Mean

63

-

-

 

Range

42-84

-

-

Stage b

    
 

IB

 

1

2

 

IIA

 

7

10

 

IIB

 

29

42

 

III

 

10

14

 

IV

 

22

32

Grading

    
 

Not reported

 

32

46

 

1

 

4

6

 

2

 

16

23

 

3

 

17

25

Primary site

    
 

Head

 

49

71

 

Body

 

6

9

 

Tail

 

5

7

 

Body-Tail

 

9

13

ECOG PS

    
 

Not reported

 

10

14

 

0

 

32

47

 

1

 

25

36

 

≥2

 

2

3

Surgery with radical intent

    
 

Yes

 

39

57

 

No

 

30

43

Baseline CA19.9 (IU/ml)

    
 

Evaluable

 

63

91

 

Mean

3052

-

-

 

Median

500

-

-

 

Range

2- > 12000

-

-

First-line chemotherapy c

    
 

Evaluable

 

59

86

 

Gem

 

43

73

 

Gem/Oxal

 

10

17

 

Gem/5-FU

 

3

5

 

Non-Gem

 

1

2

 

No CT

 

2

3

ENOA1,2 Reactivity

    
 

Evaluable

 

50

73

 

Positive

 

34

68

 

Negative

 

16

32

  1. ECOG PS eastern cooperative oncology group performance status, 5-FU 5-fluorouracil, Gem gemcitabine, Oxal oxaliplatin, CT chemotherapy.
  2. aRounded percentages.
  3. bClassified according to the TMN classification of malignant tumor of the pancreas (UICC).
  4. cFirst-line chemotherapy refers to palliative chemotherapy administered for relapsed, locally advanced inoperable, or metastatic disease.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us